SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 8.18% Stake in Outlook Therapeutics

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 8.18% in Outlook Therapeutics, Inc., totaling 2,220,000 shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have filed an Amendment No. 2 to Schedule 13G, disclosing their beneficial ownership in Outlook Therapeutics, Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 2,220,000 shares of Outlook Therapeutics' Common Stock.
• This aggregate amount represents 8.18% of the company's outstanding Common Stock.
• The ownership includes warrants to purchase 1,443,000 shares held by Biomedical Value Fund, L.P. and 777,000 shares held by Biomedical Offshore Value Fund, Ltd., totaling 2,220,000 shares.
• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point, have shared voting and investment power over these shares.
• The percentage is calculated based on 24,905,635 shares outstanding as reported by Outlook Therapeutics in its Form 10-K on November 14, 2024, plus the 2,220,000 shares issuable from warrants.
• The warrants are subject to a Beneficial Ownership Cap, restricting exercise if it would lead to ownership exceeding 9.99% of the outstanding shares, though the current reported ownership is below this cap.
• The reporting persons disclaim beneficial ownership of the shares underlying the warrants except to the extent of their pecuniary interests.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Positives

• The disclosure of a significant ownership stake by an investment firm (Great Point Partners) and its principals may signal confidence in Outlook Therapeutics, Inc.
• The continued holding of a substantial percentage (8.18%) indicates a sustained interest from these institutional investors.

Risks

• The Beneficial Ownership Cap on warrants (9.99%) could limit the ability of the reporting persons to increase their stake beyond a certain threshold through warrant exercise, potentially impacting their influence or future investment strategy.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (8.18%) by Great Point Partners and its principals may be viewed positively, signaling investor confidence and potentially influencing other investors' perceptions of Outlook Therapeutics. It also clarifies who holds substantial voting and dispositive power over a portion of the company's shares.

Key Dates

Keywords

Outlook Therapeutics, OTLK, Schedule 13G, Beneficial Ownership, Great Point Partners, Institutional Investor, Warrants, Common Stock, SEC Filing, Investment Disclosure, Biomedical Value Fund, Biomedical Offshore Value Fund